Merck KGaA is a leading German science and technology enterprise. Its business operations are strategically organized into three core divisions: Life Science, Healthcare, and Electronics. The Life Science segment provides an extensive portfolio of tools, chemicals, and equipment essential for academic research laboratories, biotech firms, pharmaceutical manufacturers, and the broader industrial sector. This division also furnishes drug developers with specialized process development expertise and advanced technologies, such as continuous bioprocessing, alongside a variety of testing kits, reagents, and associated services. Furthermore, it delivers analytical solutions for environmental monitoring (air, water, and soil) and products designed to evaluate nutritional content and detect quality deviations. The Healthcare segment focuses on the discovery, development, manufacturing, and commercialization of prescription drugs and biopharmaceuticals. Its therapeutic areas encompass oncology, neurology and immunology, fertility, endocrinology, cardiovascular conditions, diabetes, thyroid disorders, and multiple sclerosis. This segment also markets general medicines and integrates medical technology, including injection devices and disease monitoring software. The Electronics segment supplies critical materials to the semiconductor and display industries. It also specializes in surface design solutions, offering comprehensive delivery systems, services, and innovative surface products, which include cosmetic ingredients, effect pigments, and various functional applications. Beyond its internal operations, Merck KGaA actively pursues strategic collaborations. This includes in-licensing agreements, such as with Debiopharm International SA for drug candidates targeting head and neck cancer; with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for treatments against metastatic colorectal cancer; and with Abbisko Therapeutics Co. Ltd. for therapies for tenosynovial giant cell tumor. The company also holds a license and collaboration agreement dedicated to identifying two targeted protein degraders for vital oncogenic proteins. Established in 1668, Merck KGaA boasts a long and distinguished history and is headquartered in Darmstadt, Germany. The company functions as a subsidiary under the umbrella of E. Merck KG.
The share count has stayed roughly flat over this period — little dilution or buyback activity.
Diluted shares outstanding: 2.17B (2021) → 2.17B (2025)
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Earnings per share down more than 10%. Either a bad year, or a real decline.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Interest coverage above 8. Profits cover interest many times over.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
P/E above the market average. People are paying up for expected growth.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Modest yield. The bulk of any return needs to come from price appreciation.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
